Lipids include a broad family of molecules, ranging from fatty acids and triglycerides to cholesterol, phospholipids and sphingolipids. Tumour cells can increase the production of fatty acids through de novo lipogenesis, import lipids from the circulation or absorb them from neighbouring cells. Enzymes such as ATP-citrate lyase, acetyl-CoA carboxylase and fatty acid synthase help convert carbon from glucose and other nutrients into lipid building blocks. These molecules are then incorporated into cellular membranes, stored in lipid droplets or transformed into bioactive mediators. Because rapidly dividing cancer cells must create new membranes while maintaining energy production under stressful conditions, metabolic flexibility can provide a major survival advantage.

The tumour microenvironment intensifies this advantage. Cancer-associated fibroblasts, adipocytes, endothelial cells and immune cells exchange nutrients and signalling molecules with malignant cells. Adipose tissue, for example, can release free fatty acids that are taken up by tumours and oxidised in mitochondria to generate ATP. Lipid droplets can act as intracellular reserves, protecting fatty acids from toxic accumulation while making them available when oxygen or nutrients become scarce. In addition, hypoxia and other stresses within solid tumours can alter lipid synthesis and storage. These adaptations may help cancer cells continue to grow, invade surrounding tissues and resist chemotherapy, radiation or targeted treatment.

Lipid metabolism also affects the physical behaviour of tumours. Changes in membrane composition can influence receptor activity, vesicle trafficking and the formation of structures that enable migration and invasion. Cholesterol-rich membrane domains, often called lipid rafts, can organise growth-factor receptors and downstream signalling proteins, potentially strengthening pathways that promote proliferation. Fatty acids can also be converted into eicosanoids and other mediators that regulate inflammation, blood-vessel formation and tissue remodelling. Such signals may help establish conditions in which malignant cells move more efficiently through tissue and create new blood supplies, while simultaneously modifying how immune cells interpret the tumour.

The immune system is particularly sensitive to the lipid environment. T cells require carefully coordinated metabolic programmes when they become activated, multiply and attack abnormal cells. However, the tumour microenvironment is often poor in glucose and oxygen while containing excessive lipids, lactate and other metabolic by-products. Under these conditions, cytotoxic T cells and natural killer cells may lose functional capacity. Excessive lipid uptake or lipid peroxidation can damage immune-cell membranes and organelles, while changes in mitochondrial metabolism can reduce the production of molecules needed for effective killing. The result may be exhaustion, a state in which immune cells remain present but show diminished proliferation, cytokine production and cytotoxic activity.

Other immune populations can be reshaped in the opposite direction. Tumour-associated macrophages may accumulate lipids and adopt phenotypes that support tissue repair, angiogenesis and immune suppression rather than direct tumour destruction. Myeloid-derived suppressor cells can interfere with T-cell activation through nutrient competition, production of inhibitory molecules and modulation of inflammatory signalling. Regulatory T cells may be comparatively well adapted to the nutrient conditions within tumours, allowing them to persist and restrain anti-tumour responses. The review highlights the importance of viewing these populations as metabolically interconnected rather than analysing each immune cell in isolation. A lipid pathway that supports one cell type may impair another, producing complex effects across the tumour ecosystem.

Lipid-derived signals can also influence immune checkpoints and inflammatory networks. Oxidised lipids, prostaglandins and specialised sphingolipid metabolites can alter cytokine release, antigen presentation and the recruitment of immune cells. In some contexts, they promote chronic inflammation that helps cancer progression; in others, they suppress the signals required for an effective immune attack. This complexity helps explain why simply blocking lipid synthesis may not produce the same result in every tumour. The consequences may depend on cancer type, genetic background, diet, tissue location, oxygen availability and the composition of the surrounding immune population. A metabolic intervention could theoretically weaken malignant cells while improving immune function, but it might also create compensatory pathways that allow either cancer or immune cells to adapt.

These connections are relevant to modern immunotherapy. Immune-checkpoint inhibitors, including therapies targeting the PD-1, PD-L1 or CTLA-4 pathways, rely on the presence of immune cells capable of recovering anti-tumour activity. If those cells are metabolically paralysed by the tumour environment, releasing an inhibitory checkpoint may be insufficient. Researchers are therefore investigating combinations that pair immunotherapy with inhibitors of fatty-acid synthesis, lipid uptake, cholesterol handling or specific inflammatory pathways. Other approaches aim to reprogramme macrophages, reduce suppressive myeloid-cell activity or protect T-cell mitochondria. The challenge is achieving selective targeting: lipid metabolism is essential not only to tumours but also to normal tissues, immune surveillance and tissue repair.

The review also points toward the need for better biomarkers and more precise experimental tools. Measuring lipid metabolism from a single blood sample may not reveal what is occurring inside a tumour, where different regions can have sharply different nutrient conditions. Technologies such as lipidomics, spatial transcriptomics, single-cell sequencing and metabolic imaging can help map which cells produce, consume or transform particular lipids. These approaches could identify patients whose tumours depend on specific metabolic circuits or reveal why a treatment works in one cancer but fails in another. Yet translating such findings into clinical therapy will require careful attention to toxicity, drug delivery and the possibility that tumours reroute metabolism when one pathway is blocked.

By bringing cancer metabolism and anti-cancer immunity into the same framework, Koh and colleagues present lipids as potential therapeutic targets and as indicators of how tumours evolve under pressure. The central message is that malignant growth is not governed by tumour-cell genetics alone; it is also shaped by nutrient exchange and metabolic competition throughout the tumour microenvironment. Future treatments may therefore combine conventional anti-cancer drugs with strategies that remodel lipid availability, restore immune-cell fitness and prevent suppressive signalling. The field remains technically challenging, but understanding how fats function as fuel, membrane material and immune-regulatory messengers could open a new route toward therapies designed to attack cancer while strengthening the body’s own defences.

Subject of Research: The interplay between lipid metabolism, cancer progression and anti-cancer immunity

Article Title: The interplay between lipid metabolism, cancer progression and anti-cancer immunity

Article References: Koh, CH., Lee, Y., Kim, IK. et al. The interplay between lipid metabolism, cancer progression and anti-cancer immunity. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01783-3

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01783-3

At the cellular level, lipids serve fundamental roles as building blocks of membranes, signaling molecules, and energy reservoirs. Tumor cells exploit these lipids, notably fatty acids, cholesterol, and lipid droplets, to fuel aberrant growth and metastasis. Enzymatic systems such as ATP citrate lyase and acyl-CoA synthetase are upregulated to enable enhanced de novo fatty acid synthesis. Concurrently, fatty acid oxidation (FAO) facilitates invasive behaviors, while the saturation levels of fatty acids modulate membrane fluidity and receptor-mediated signal transduction, reinforcing tumor resilience.

Cholesterol metabolism also undergoes substantial alterations in cancerous tissues. Elevated activity of cholesterol esterification enzymes, particularly acyl-CoA:cholesterol acyltransferase (ACAT), leads to the accumulation of lipid droplets that serve as storage depots within tumor cells. These lipid reservoirs support membrane biosynthesis and act as reservoirs for signaling lipids, directly influencing oncogenic pathways regulated by transcription factors such as SREBP2, and signaling cascades including Hedgehog and Notch. This lipid storage mechanism is increasingly recognized as a key contributor to tumor aggressiveness.

Lipid droplets, far from being passive entities, are dynamically regulated organelles critical for maintaining lipid homeostasis in cancer cells. Proteins like PLIN2 coat these droplets, while transcription factors such as FOXO3 govern their metabolism. Dysregulated lipophagy and lipolysis not only mobilize lipid stores but also generate reactive oxygen species (ROS), which paradoxically can promote tumor survival by activating adaptive stress responses. This paradox underscores the intricate balancing act cancer cells perform to thrive under hostile conditions.

The influence of lipid metabolism extends into the tumor immune microenvironment (TIME), where it fundamentally affects immune cell function and fate. Tumor cells create a metabolically hostile milieu characterized by nutrient competition and oxidative stress, which hampers the efficacy of antitumor immune cells and fosters immunosuppression. This metabolic crosstalk is especially evident in various immune subsets, including T cells, dendritic cells, myeloid-derived suppressor cells (MDSCs), natural killer (NK) cells, and macrophages.

T cells, pivotal effectors of adaptive immunity, undergo metabolic adaptations within the tumor niche. Regulatory T cells (Tregs) preferentially utilize FAO and oxidative phosphorylation (OXPHOS) to meet their energetic needs, facilitating their suppressive roles. In contrast, effector T cells depend largely on glycolytic metabolism, rendering them vulnerable to nutrient deprivation and ROS-induced dysfunction. These metabolic constraints significantly impair effective tumor eradication.

Dendritic cells (DCs), essential for antigen presentation and T cell priming, are also hindered by aberrant lipid accumulation in the tumor microenvironment. Lipid overload disrupts their antigen-processing capacity, suppressing their activation. Interestingly, pharmacological inhibition of FAO in DCs has been shown to restore their immunostimulatory functions, suggesting therapeutic avenues targeting cholesterol and fatty acid metabolism to reverse immune tolerance and potentiate immunotherapy.

MDSCs, notorious for their immunosuppressive capacity, rely on lipid metabolic pathways to sustain their function. Specifically, FAO and arachidonic acid metabolism mediated by fatty acid transporter protein 2 (FATP-2) bolster their ability to inhibit T cell responses. Targeting these pathways suppresses MDSC activity, reawakening antitumor immunity and delaying tumor progression—an insight that opens new doors for combinatorial cancer therapies.

Natural killer (NK) cells require balanced lipid metabolism for optimal cytotoxic function, with the mechanistic target of rapamycin (mTOR) pathway acting as a key regulator. Macrophages within the tumor environment demonstrate polarization into distinct phenotypes. M1 macrophages possess pro-inflammatory and tumoricidal properties, whereas M2-like tumor-associated macrophages (TAMs) utilize FAO and secrete immunosuppressive cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β) that facilitate tumor growth and immune evasion.

The identification of lipid metabolism-associated molecules as biomarkers is gaining traction in cancer diagnostics. Enzymes like fatty acid synthase (FASN), transporters such as FATP, bioactive lipids including ceramides, oxysterols, and lysophosphatidylcholine (LPC) exhibit correlative expression with tumor progression and immune modulation. Their detection in biological fluids represents a promising strategy for early cancer detection, prognosis, and therapeutic guidance.

From a preventive perspective, alterations in lipid metabolites can herald the incipient stages of oncogenesis. Non-invasive monitoring of these metabolites in blood or tissue harbors immense potential for early screening initiatives. Modulating lipid metabolism, whether by inhibiting fatty acid synthesis pathways or amplifying fatty acid oxidation, offers a prospective avenue for interrupting tumor initiation before malignant transformation manifests clinically.

Immunotherapy, a transformative paradigm in cancer treatment, benefits markedly from integration with lipid-targeted strategies. Inhibitors of lipid uptake molecules like CD36 alleviate immunosuppression by reducing lipid overload in immune cells. Furthermore, lipid-based drug delivery systems, exemplified by liposomes, enhance the precision and efficacy of chemotherapeutic and immunomodulatory agents. Advances in understanding ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation, provide a novel mechanistic target that exploits cancer cells’ metabolic vulnerabilities.

Looking ahead, the clinical translation of these insights hinges on several critical fronts. The refinement of lipid metabolism biomarkers for routine diagnostic use promises to revolutionize early cancer detection paradigms. Concurrently, optimizing lipid-centric drug delivery platforms will enhance therapeutic index and patient outcomes. Integrating immunometabolism within personalized oncology frameworks holds the key to tailoring combinatorial approaches that harness both metabolic modulation and immune activation for superior efficacy.

In summary, lipid metabolism is no longer merely a supporting player but rather a central orchestrator in the complex narrative of tumorigenesis and immune regulation. Its reprogramming empowers cancer cells with survival advantages while sculpting an immunosuppressive microenvironment. Targeting these lipid pathways offers a transformative strategy that bridges early diagnosis, effective prevention, and cutting-edge immunotherapy, heralding a new era in cancer management. Continued rigorous research into these metabolic intricacies will undoubtedly propel the development of next-generation interventions poised to curtail the global cancer burden.

Subject of Research: Lipid metabolism and its role in tumor biology and immune microenvironment with implications for early cancer diagnosis and prevention.

Article Title: Lipid Metabolic Reprogramming and the Tumor Immune Microenvironment: A New Strategy for Early Diagnosis and Cancer Prevention

News Publication Date: 30-Mar-2025

Web References:
https://www.xiahepublishing.com/journal/csp
http://dx.doi.org/10.14218/CSP.2025.00002

Image Credits: Ruihua Shi, Xiaoshuang Liu, Jihua Ren

Keywords: Lipid metabolism, Cancer screening, Immunotherapy, Tumor immune microenvironment, Fatty acid oxidation, Cholesterol metabolism, Lipid droplets, Ferroptosis